Eli Lilly and Amylin Pharmaceuticals Announces BYDUREON Receives Marketing Authorization in Europe

Eli Lilly and Company LLY, together with Amylin Pharmaceuticals, Inc. AMLN and Alkermes, Inc. ALKS, announced today that the European Commission has granted marketing authorization to BYDUREON. BYDUREON, a glucagon-like peptide-1 receptor agonist, is the first once-weekly treatment for type 2 diabetes. It delivers glycemic control in a single weekly dose and is indicated for the treatment of type 2 diabetes in adult patients in combination with metformin, a sulfonylurea, a thiazolidinedione, metformin plus a sulfonylurea or metformin plus a thiazolidinedione.